Dr. Sarah Chen
June 12, 2026
Obstructive sleep apnea (OSA) affects an estimated 30% of adults with obesity, and the two conditions share bidirectional pathophysiology—excess pharyngeal adipose tissue narrows the upper airway, while sleep fragmentation impairs metabolic regulation and increases weight gain. Traditional OSA therapeutics (continuous positive airway pressure, oral appliances, surgery) address mechanical airway collapse but do not treat the underlying metabolic dysfunction. Pharmacologic interventions targeting obesity-driven OSA remain limited, creating a clinical gap that retatrutide's triple agonism may address.
On June 6, 2026, Eli Lilly presented Phase 3 results from TRIUMPH-1 at the American Diabetes Association's 86th Scientific Sessions, reporting substantial improvements in OSA severity alongside weight reduction. These findings represent the first comprehensive evaluation of a triple hormone receptor agonist in a prospectively designed, nested basket trial for moderate-to-severe OSA comorbid with obesity.
TRIUMPH-1 operated as a master protocol with an overarching obesity trial and two nested basket studies. The OSA-specific cohort enrolled 243 adults with obesity (BMI ≥30 kg/m²) and baseline moderate-to-severe obstructive sleep apnea, defined as apnea-hypopnea index (AHI) ≥15 events per hour. Participants were randomized 1:1:1:1 to once-weekly subcutaneous injections of retatrutide 4 mg, 9 mg, 12 mg, or placebo for 80 weeks, with an option for pre-specified extension to 104 weeks in participants with baseline BMI ≥35.
The trial employed a double-blind, placebo-controlled, randomized design across multiple global sites. All participants received standardized lifestyle counseling on diet and physical activity. The primary efficacy endpoint was change in apnea-hypopnea index (AHI) from baseline to 80 weeks. Secondary endpoints included body weight change, BMI reduction, and safety/tolerability assessments. Sleep apnea severity was measured via in-home or laboratory polysomnography at baseline and endpoint.
Retatrutide demonstrated dose-dependent reductions in AHI across all three active treatment arms compared with placebo:
Absolute AHI Reduction (events per hour): - Retatrutide 4 mg: significant reduction from baseline (specific magnitude not disclosed in available data) - Retatrutide 9 mg: significant reduction from baseline (specific magnitude not disclosed in available data) - Retatrutide 12 mg: (60.6% relative reduction) from baseline of 58.6 events/hour
This 60.6% reduction represents the most substantial pharmacologic OSA improvement reported in a Phase 3 trial to date. For context, the baseline AHI of 58.6 events/hour reflects severe OSA (AHI ≥30 is classified as severe); the endpoint reduction to approximately 22.5 events/hour represents moderate OSA, a clinically meaningful transition that may reduce apnea-related arousals, hypoxemic burden, and cardiovascular strain.
All three retatrutide doses achieved statistical significance versus placebo, indicating dose-dependent efficacy with the 12 mg dose yielding maximum benefit. The trial met its primary endpoint across all active treatment groups.
The OSA improvement paralleled retatrutide's weight loss efficacy in the broader TRIUMPH-1 cohort:
This correlation suggests that obesity-driven airway collapse reversal—through reduction of pharyngeal and parapharyngeal adipose tissue—constitutes the primary mechanism of OSA improvement rather than direct neurobiological effects on upper airway tone or arousal threshold. The triple agonist mechanism likely operates through multiple pathways:
Beyond AHI reduction, retatrutide treatment in TRIUMPH-1 participants with OSA demonstrated:
No unexpected safety signals emerged in the OSA population. Detailed safety data remain pending full peer-reviewed publication.
Retatrutide's simultaneous activation of GIP, GLP-1, and glucagon receptors provides a mechanistic rationale for OSA improvement beyond single-agonist approaches:
GLP-1 receptor agonism enhances insulin secretion, improves insulin sensitivity, and reduces appetite—effects that promote weight loss and may reduce systemic inflammation contributing to airway edema.
GIP receptor agonism (glucose-dependent insulinotropic polypeptide, formerly glucose-dependent insulinotropic peptide) enhances insulin secretion in a glucose-dependent manner and may improve metabolic efficiency, potentially contributing to preferential visceral fat loss.
Glucagon receptor agonism increases hepatic glucose output and energy expenditure, driving metabolic rate elevation and lipid mobilization. Glucagon's role in the triple agonist distinguishes retatrutide from dual GLP-1/GIP agents (tirzepatide) and may explain incremental weight loss and metabolic benefits.
The convergence of these three pathways likely produces synergistic weight loss and metabolic improvement, translating to more robust OSA reversal than would be expected from weight loss alone.
TRIUMPH-1's OSA findings expand the therapeutic landscape for obesity-related sleep apnea. Current standard-of-care therapies—CPAP, oral appliances, and surgery—address mechanical obstruction but do not treat metabolic dysfunction. Pharmacologic agents targeting obesity itself may offer a complementary or alternative approach, particularly for patients with CPAP intolerance or inadequate response.
The nested basket design of TRIUMPH-1 positions OSA as a potential label indication for retatrutide. Eli Lilly has announced plans to submit retatrutide for regulatory review by the end of 2026, contingent on completion of Phase 3 trials in obesity, knee osteoarthritis, and OSA. OSA approval would represent the first FDA-approved pharmacotherapy specifically indicated for obesity-driven sleep apnea.
While TRIUMPH-1 OSA data are compelling, several limitations warrant acknowledgment:
As of June 2026, TRIUMPH-1 OSA results were presented at the American Diabetes Association Scientific Sessions but have not yet been published in a peer-reviewed journal. The companion TRANSCEND-T2D-1 trial (type 2 diabetes) was simultaneously published in [The Lancet](https://www.thelancet.com/), suggesting that detailed TRIUMPH-1 manuscripts are in preparation. Researchers should monitor [PubMed](https://pubmed.ncbi.nlm.nih.gov/) and journal websites for full publications containing detailed statistical analyses, safety tables, and mechanistic insights.
TRIUMPH-1 Phase 3 data demonstrate that retatrutide, a first-in-class GIP/GLP-1/glucagon triple agonist, achieves a 60.6% reduction in apnea-hypopnea index in adults with obesity and moderate-to-severe obstructive sleep apnea. This efficacy, coupled with substantial weight loss and cardiometabolic improvements, positions retatrutide as a potential pharmacologic option for obesity-driven OSA. The triple agonist mechanism likely operates through synergistic weight loss and metabolic remodeling rather than direct airway-specific effects. Pending full peer-reviewed publication and regulatory review, these findings may reshape clinical approaches to obesity-related sleep apnea and expand the therapeutic armamentarium beyond traditional mechanical and surgical interventions.